Identification and Characterization of Heteroclitic Peptides in TCR-binding Positions with Improved HLA-binding Efficacy

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2021 Feb 27

PMID 33637105

Citations 9

Authors

Beatrice Cavalluzzo

Concetta Ragone

Angela Mauriello

Annacarmen Petrizzo

Carmen Manolio

Andrea Caporale

Luigi Vitagliano

Menotti Ruvo

Luigi Buonaguro

Maria Tagliamonte

Affiliations

Soon will be listed here.

Abstract

The antigenicity as well as the immunogenicity of tumor associated antigens (TAAs) may need to be potentiated in order to break the immunological tolerance. To this aim, heteroclitic peptides were designed introducing specific substitutions in the residue at position 4 (p4) binding to TCR. The effect of such modifications also on the affinity to the major histocompatibility class I (MHC-I) molecule was assessed. The Trp2 antigen, specific for the mouse melanoma B16F10 cells, as well as the HPV-E7 antigen, specific for the TC1 tumor cell lines, were used as models. Affinity of such heteroclitic peptides to HLA was predicted by bioinformatics tools and the most promising ones were validated by structural conformational and HLA binding analyses. Overall, we demonstrated that TAAs modified at the TCR-binding p4 residue are predicted to have higher affinity to MHC-I molecules. Experimental evaluation confirms the stronger binding, suggesting that this strategy may be very effective for designing new vaccines with improved antigenic efficacy.

Citing Articles

Short Peptides as Powerful Arsenal for Smart Fighting Cancer.

Bojarska J, Wolf W Cancers (Basel). 2024; 16(19).

PMID: 39409876 PMC: 11476321. DOI: 10.3390/cancers16193254.

Recent Findings on Therapeutic Cancer Vaccines: An Updated Review.

Sheikhlary S, Lopez D, Moghimi S, Sun B Biomolecules. 2024; 14(4).

PMID: 38672519 PMC: 11048403. DOI: 10.3390/biom14040503.

Structural and Dynamic-Based Characterization of the Recognition Patterns of E7 and TRP-2 Epitopes by MHC Class I Receptors through Computational Approaches.

Balasco N, Tagliamonte M, Buonaguro L, Vitagliano L, Paladino A Int J Mol Sci. 2024; 25(3).

PMID: 38338663 PMC: 10855917. DOI: 10.3390/ijms25031384.

Peptide-based vaccine for cancer therapies.

Buonaguro L, Tagliamonte M Front Immunol. 2023; 14:1210044.

PMID: 37654484 PMC: 10467431. DOI: 10.3389/fimmu.2023.1210044.

Proceedings of the Online Conference "Vaccines and Vaccination during and Post COVID Pandemics" (7-9 December 2022).

Sokolovska L, Isaguliants M, Buonaguro F Vaccines (Basel). 2023; 11(7).

PMID: 37514990 PMC: 10383049. DOI: 10.3390/vaccines11071175.

References

Stone J, Chervin A, Kranz D . T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunology. 2009; 126(2):165-76. PMC: 2632691. DOI: 10.1111/j.1365-2567.2008.03015.x. View

Carrabba M, Castelli C, Maeurer M, Squarcina P, Cova A, Pilla L . Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues. Cancer Res. 2003; 63(7):1560-7. View

Bae J, Samur M, Munshi A, Hideshima T, Keskin D, Kimmelman A . Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells. Oncoimmunology. 2015; 3(12):e970914. PMC: 4356023. DOI: 10.4161/21624011.2014.970914. View

Hawse W, De S, Greenwood A, Nicholson L, Zajicek J, Kovrigin E . TCR scanning of peptide/MHC through complementary matching of receptor and ligand molecular flexibility. J Immunol. 2014; 192(6):2885-91. PMC: 3992338. DOI: 10.4049/jimmunol.1302953. View

Tissot A, Ciatto C, Mittl P, Grutter M, Pluckthun A . Viral escape at the molecular level explained by quantitative T-cell receptor/peptide/MHC interactions and the crystal structure of a peptide/MHC complex. J Mol Biol. 2000; 302(4):873-85. DOI: 10.1006/jmbi.2000.4501. View

Birnbaum M, Mendoza J, Sethi D, Dong S, Glanville J, Dobbins J . Deconstructing the peptide-MHC specificity of T cell recognition. Cell. 2014; 157(5):1073-87. PMC: 4071348. DOI: 10.1016/j.cell.2014.03.047. View

RAMMENSEE H, Bachmann J, Emmerich N, Bachor O, Stevanovic S . SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 1999; 50(3-4):213-9. DOI: 10.1007/s002510050595. View

Dyson J . T-cell receptors: tugging on the anchor for a tighter hold on the tumor-associated peptide. Eur J Immunol. 2015; 45(2):380-2. DOI: 10.1002/eji.201445385. View

Binkowski T, Marino S, Joachimiak A . Predicting HLA class I non-permissive amino acid residues substitutions. PLoS One. 2012; 7(8):e41710. PMC: 3414483. DOI: 10.1371/journal.pone.0041710. View

10.

Madura F, Rizkallah P, Holland C, Fuller A, Bulek A, Godkin A . Structural basis for ineffective T-cell responses to MHC anchor residue-improved "heteroclitic" peptides. Eur J Immunol. 2014; 45(2):584-91. PMC: 4357396. DOI: 10.1002/eji.201445114. View

11.

Rammensee H, Friede T, Stevanoviic S . MHC ligands and peptide motifs: first listing. Immunogenetics. 1995; 41(4):178-228. DOI: 10.1007/BF00172063. View

12.

Moise L, Gutierrez A, Bailey-Kellogg C, Terry F, Leng Q, Abdel Hady K . The two-faced T cell epitope: examining the host-microbe interface with JanusMatrix. Hum Vaccin Immunother. 2013; 9(7):1577-86. PMC: 3974887. DOI: 10.4161/hv.24615. View

13.

Parkhurst M, Salgaller M, Southwood S, Robbins P, Sette A, Rosenberg S . Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol. 1996; 157(6):2539-48. View

14.

Chen J, Dunbar P, Gileadi U, Jager E, Gnjatic S, Nagata Y . Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol. 2000; 165(2):948-55. DOI: 10.4049/jimmunol.165.2.948. View

15.

Caporale A, Doti N, Sandomenico A, Ruvo M . Evaluation of combined use of Oxyma and HATU in aggregating peptide sequences. J Pept Sci. 2017; 23(4):272-281. DOI: 10.1002/psc.2977. View

16.

Hunt D, Henderson R, Shabanowitz J, Sakaguchi K, Michel H, Sevilir N . Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science. 1992; 255(5049):1261-3. DOI: 10.1126/science.1546328. View

17.

Circelli L, Petrizzo A, Tagliamonte M, Heidenreich R, Tornesello M, Buonaguro F . Immunological effects of a novel RNA-based adjuvant in liver cancer patients. Cancer Immunol Immunother. 2016; 66(1):103-112. PMC: 11028778. DOI: 10.1007/s00262-016-1923-5. View

18.

Parker K, Bednarek M, Hull L, Utz U, Cunningham B, Zweerink H . Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2. J Immunol. 1992; 149(11):3580-7. View

19.

Dao T, Korontsvit T, Zakhaleva V, Jarvis C, Mondello P, Oh C . An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules. Oncoimmunology. 2017; 6(2):e1252895. PMC: 5353933. DOI: 10.1080/2162402X.2016.1252895. View

20.

Petrizzo A, Caruso F, Tagliamonte M, Tornesello M, Ceccarelli M, Costa V . Identification and Validation of HCC-specific Gene Transcriptional Signature for Tumor Antigen Discovery. Sci Rep. 2016; 6:29258. PMC: 4937235. DOI: 10.1038/srep29258. View